Damora Therapeutics (DMRA) Q3 2026 earnings review
Damora starts human trials, but a rival drug is ahead
Damora Therapeutics, which develops antibody drugs for a group of blood cancers, started enrolling patients in its first trial. Chief executive Jennifer Jarrett said several clinical sites have opened. Research now takes most of its spending, and the quarterly loss reached $32 million. Its $528 million in cash and investments should last into the second half of 2029, Damora said.
| Net loss | $32.0M $29.5M a quarter on average in the first half |
|---|---|
| Cash and investments | $528.5M $257.6M at the end of 2025 |
| Cash used in operations | $17.2M $21.2M a quarter on average in the first half |
| Cash runway outlook | Into second half of 2029 |
⚖️ Verdict: 🟢 Bullish
The story got better because the lead drug moved from lab tests into a human trial with clearance from US regulators. One caution: a rival antibody reached patients first, Damora admits, and its lab comparisons used an in-house reference. By our math, its cash plan allows spending at more than twice this quarter's pace.
The question now is whether DMR-001 beats that rival in patients. Either its stronger binding in the lab carries over to people, or the rival's earlier start decides which drug doctors use. The first of two trial readouts, due from mid-2027, will tell.
🐂 Bull Case
Damora's Lead Drug Entered Its First Human Trial
DMR-001 is Damora's lead drug, an antibody aimed at mutant calreticulin (mutCALR), a faulty protein behind some blood cancers. Chief executive Jennifer Jarrett said the biotech has "continued to execute with urgency, initiating enrollment at multiple clinical sites". The trial, called CLARITY-101, tests the drug in two of those cancers.
Essential thrombocythemia makes the body produce too many platelets, and myelofibrosis scars the bone marrow. Health authorities in Australia let Damora open the trial in the quarter, and the US Food and Drug Administration cleared it soon after. Doctors start patients on 100 mg, injected under the skin once a month.
- Lab studies and trial work: 31.5% of research spending, against 17.0% in the first half
- Drug manufacturing work: 30.9% of research spending, against 40.1% in the first half
- Lab studies and trial work: $8.0 million in the quarter
This matters because the money now follows the patients. Spending on trial work caught up with the cost of making the drug supply, so Damora has moved from preparing the drug to testing it. The trial design aims for "rapid identification of a recommended dose for Phase 1b expansion cohorts", the larger patient groups that follow.
What to watch: the date Damora reports giving DMR-001 to its first patient, and how many trial sites it opens by year-end. Quick progress through the higher doses would keep the two readouts it plans from mid-2027 on schedule.
Damora Now Holds a Licence to Two Drugs
Until November, Damora held only an option on the antibodies that Paragon Therapeutics, the lab that discovered them, built for it. On November 3 the biotech signed a licence for DMR-001 and DMR-002, which it describes as an "exclusive, worldwide, royalty-bearing license".
- Milestone payments: up to $22.0 million per drug, including those already paid
- Paid so far: $1.5 million for each of the two drugs
- Royalties: low to mid single-digit percentages of net sales
The terms matter because they stay small next to the cash Damora holds. So if the drugs reach the market, most of the sales income would stay with Damora's owners. But DMR-003, its third drug, still sits under an option that Damora has not exercised.
What to watch: whether Damora exercises its option on DMR-003, an antibody that directs the immune system's T cells against cancer cells, and on what terms. Similar terms would give Damora the same low costs on all three drugs.
🐻 Bear Case
Damora Will Need New Money Before Approval
Damora says its cash will fund operations into the second half of 2029. Yet it plans to start late-stage testing of DMR-001, the largest and costliest phase, as early as mid-2028. In its quarterly filing, the biotech wrote that "we will need to obtain substantial additional funding to finance our continuing operations".
This quarter's cash outflow also looks lighter than the costs behind it. Pay in shares explains most of the gap between cash spent and the loss. Unpaid bills to suppliers covered about $6 million more, by our math, and those bills will come due.
- Cash used in operations: $17.2 million, against $21.2 million a quarter in the first half
- Unpaid contract research bills: $9.4 million, against $0.3 million at the end of 2025
- Unused capacity to sell new shares gradually on the market: $114.7 million
What to watch: cash used in operations in the fourth quarter, when the trial adds sites and DMR-002, its second antibody, nears its first regulatory filing. A sharp step up would bring the next share sale closer and dilute today's owners.
A Rival Antibody Entered Patient Trials First
Chief executive Jennifer Jarrett said DMR-001, Damora's antibody against a faulty protein called mutCALR, has "potentially best-in-class pan-mutant activity across the full range of CALR mutations". Pan-mutant means it works against every form of the faulty protein. Damora said new lab data show a 95-fold average gain against 10 rarer mutations.
The comparison has limits that the filing itself states. Damora measured DMR-001 against "a reference mutCALR monoclonal antibody that we generated internally for research purposes", not against a rival drug. It also wrote that its comparisons rest on lab studies "and not on head-to-head clinical trials".
Meanwhile another company already tests INCA033989, an antibody against the same target, in patients. Damora's filing opens one sentence with "Although DMR-001 is not the first anti-mutCALR antibody to enter the clinic", then argues its drug can still be the best.
This cuts against the best-in-class claim, because doctors will judge DMR-001 against the rival's patient results, not an in-house reference. So the later arrival must show clearly better blood counts or easier dosing, such as Damora's planned monthly injection.
What to watch: the rival's next patient data, then Damora's first readout from mid-2027. If DMR-001 cannot beat the rival on results or dosing, the rival's earlier entry will count for more than any lab test.
A Lab Linked to Its Investor Does Its Research
Paragon Therapeutics discovered Damora's antibodies and still runs much of its research. Fairmount, an investment firm, owns more than 5% of each company, appointed Paragon's board and holds three seats on Damora's board. Damora treats all three as related parties.
- Paragon research costs: $7.2 million in the quarter, 28% of research spending
- Warrants owed to Paramora, a Paragon vehicle: rights to buy 1% of fully diluted shares for each of 2025 and 2026
- Estimated value of the 2026 warrant grant: $15.9 million
Paragon's falling share helps, because Damora now runs more of the work itself. But the warrants hand new shares to a related party, and the new licence adds milestone payments to the same group. Outside owners carry those costs without a separate vote on each one.
What to watch: the 2026 warrant grant on the last business day of December, and any deal for DMR-003. Terms that extend payments or warrants would keep moving value to the related lab.
👓 Other Themes
Interest Income Now Covers a Tenth of Costs
Damora earned $4.2 million in interest on its cash and US Treasury holdings, enough to cover about 11% of operating costs. Lower US interest rates would shrink that income. Rates also caused a $1.0 million unrealised loss on its bond holdings, which Damora says "relate to interest rates, not credit".
Damora Sold an Old Drug and Moved to Cayman
In July Damora, formerly Galecto, moved its legal home from Delaware to the Cayman Islands, though it stays a US company for tax. It also sold GB3226, an old leukaemia drug, and other legacy assets for $0.75 million upfront, plus possible milestones and royalties. That one-off gain trimmed the quarter's loss.
💲 Other KPIs
Damora's own research staff took 18.6% of research spending, up from about 10% in the first half and 5% a year ago. The biotech is adding scientists of its own as it widens the trial. Pay in shares made up $2.2 million of that staff bill.
The share count barely moved in the quarter, up 0.3%, after preferred shares converted into ordinary shares early in the year. Counting convertible preferred shares, options, restricted units and warrants, the total reaches about 87 million by our math. Damora sold 167,423 new shares in the quarter through its at-the-market programme.
🔮 Guidance
New in these materials. Damora expects $528.5 million of cash and investments to fund operations into the second half of 2029. By our math, that allows about $44 million of cash spending a quarter, roughly 2.6 times the third-quarter pace. The date falls after the planned mid-2028 start of late-stage testing, so a full final trial would need new money.
New. Damora plans two posters at the American Society of Hematology (ASH) meeting in December. One covers the drug's activity against rarer mutations of the faulty protein; the other describes the trial design. Both rest on lab work and planning, not on patient results.
New. Damora plans two early readouts from mid-2027, each an early test of whether DMR-001 works in patients. It also plans larger patient groups in 2027 and could start late-stage testing as early as mid-2028, depending on those results.
New. Damora plans the first regulatory filing for DMR-002, its second antibody, before the year ends. DMR-002 aims to help the immune system kill cancer cells that carry the faulty protein. The filing would put a second drug on the path to human testing.
New. Damora plans the first filing for DMR-003, an antibody that directs the immune system's T cells against cancer cells, in 2027. The biotech still holds only an option on this drug from Paragon, so the licence terms remain open.
❓ Key Questions
Has the first patient received DMR-001 yet?
Damora reported enrolment at several sites but not a first dose. That dose also triggers a $2.5 million payment to Paragon, so the date shows how fast the trial moves.
How fast will cash spending rise in 2027?
By our math, the runway into the second half of 2029 allows about $44 million a quarter, far above this quarter's $17.2 million. Readers need the planned path for trials, manufacturing and staff.
Will Damora license DMR-003, and on what terms?
The option on the third drug remains open. Its terms decide whether Paragon and Paramora keep receiving payments and warrants, and whether Damora covers all three ways of attacking the faulty protein.
How will Damora compare its drug with INCA033989?
Damora's lab comparisons use an in-house reference antibody. Doctors will compare patient results with the rival's, so Damora should say which measures, such as platelet counts or dosing, its readouts will report.
How much cash will a late-stage trial need?
Damora could start final-phase testing as early as mid-2028, while its cash lasts into the second half of 2029. The size of that trial decides when Damora must raise new money.